Investors & News

Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$26.36
Change (%) Stock is Up 3.33 (14.46%)
Volume1,043,907
Data as of 06/23/17 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $26.36 with a 52 week high of $31.86 and a 52 week low of $12.34.
Recent NewsMore >>
23/May/2017
Ascendis Pharma A/S Reports First Quarter 2017 Financial Results
11/May/2017
Ascendis Pharma A/S Announces First Quarter 2017 Financial Results Conference Call on May 23
28/Apr/2017
Ascendis Pharma A/S Announces Upcoming Investor Presentations
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma
E-mail: ir@ascendispharma.com

Data provided by Nasdaq. Minimum 15 minutes delayed.